Pax3 EMSA Kit
- Known as:
- Pax3 EMSA Kit
- Catalog number:
- AY1136
- Product Quantity:
- 25 rxn
- Category:
- -
- Supplier:
- Panomics
- Gene target:
- Pax3 EMSA Kit
Related genes to: Pax3 EMSA Kit
- Gene:
- PAX3 NIH gene
- Name:
- paired box 3
- Previous symbol:
- WS1
- Synonyms:
- HUP2
- Chromosome:
- 2q36.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-01-14
- Date modifiied:
- 2015-09-01
Related products to: Pax3 EMSA Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit(1-Kit) 14,15-EET_DHET Hypertension ELISA Kit Related articles to: Pax3 EMSA Kit
- -Aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the central nervous system and is involved in the development of neural tissue as well as the regulation of its functions. Meanwhile, GABA has also been demonstrated to confer multiple physiological benefits, including alleviating stress and improving metabolic homeostasis. This study investigated GABA effects on proliferation, differentiation, and temperature stress protection of bovine skeletal muscle satellite cells (BSCs). - Source: PubMed
Publication date: 2026/04/14
Manzoor AbidNaseem SajidaFu ZhiqiRuan ChaohuiLiu XuYan ChunriChoi SeonghoLi Xiangzi - Limited targeted agents are approved for pediatric sarcomas. Tyrosine kinase (TK) inhibitors (TKi) have shown clinical efficacy in some, but not all, young patients with sarcoma. A major obstacle preventing further advances and clinical implementation is the lack of predictive response biomarkers to guide TK-targeted treatments. TK-activating fusions or mutations are rare in these patients. RNA overexpression of TKs is a frequent feature. The unresolved question is when upregulated TK expression is associated with kinase activation and signaling dependence. We explored the TK molecular landscape of 107 patients with sarcoma from the ZERO Childhood Cancer Precision Medicine Program (ZERO) using whole-genome and -transcriptome sequencing. Phosphoproteomic analyses of tyrosine phosphorylation (pY) and functional in vitro and in vivo assays were performed in cell lines and patient-derived xenografts (PDX). Our analysis shows that although novel genomic driver lesions are rare, when present they are therapeutically actionable as exemplified by a novel LSM1-FGFR1 fusion identified in a patient with osteosarcoma. We further show that in certain contexts, TK RNA expression can indicate TK pathway activity and predict TKi sensitivity. We highlight the utility of FGFR inhibitors in PAX3-FOXO1 fusion-positive rhabdomyosarcomas (FP-RMS) characterized by high FGFR4 and FGF8 RNA expression levels and FGFR4 activation (FGFR4_pY). We demonstrate marked tumor growth inhibition in all FP-RMS PDXs treated with single-agent FGF401 (FGFR4-specific inhibitor) and single-agent lenvatinib (multikinase FGFR inhibitor) and report a clinical response to lenvatinib in a patient with relapsed metastatic FP-RMS. Altogether, we identified new patients with sarcoma who may benefit from FGFR inhibitors, most notably FP-RMS via FGFR4/FGF8 coexpression. - Source: PubMed
Publication date: 2026/04/27
Fordham Ashleigh MBrown Lauren MMayoh ChelseaSalib AliceBarger Zara AWong MarieLim Kam Sian Terry C CHu ChangyuanXie JinhanGunther KateTrebilcock PeterTerry Rachael LBarahona PauletteAjuyah PamelaSherstyuk AlexandraAvila AnicaCadiz RoxannePerkins Callum MGifford Andrew JMao JieDolman M Emmy MZhao AndreaO'Regan Luke PGorgels DanielLau Loretta M SZiegler David SHaber MichelleTyrrell VanessaLock Richard BCowley Mark JNicholls WayneDaly Roger JEkert Paul GFleuren Emmy D G - Occupational exposure to toxic heavy metals may render industrial workers susceptible to thyroid-related problems. Chromium (Cr) in its hexavalent form is highly toxic and a known carcinogen. This research is the first experimental study to investigate the possible protective role of adipose mesenchymal stem cell (MSC)-derived exosomes (ADMSCs-E) versus stromal vascular fraction (SVF) exosomes in a rat model of Cr-induced thyrotoxicity, using behavioral, histological, immunohistochemical, and biochemical studies, with correlation assessed using morphometric and statistical methods. - Source: PubMed
Publication date: 2026/04/10
Hosny Sara AdelShamsEldeen Asmaa MohammedMohamed Eman Emad EldinAlkaffas MarwaHassan Rokia MohamadMostafa Seham Mohamed SayedMohamed Hala Hassan - Gene mutations and altered epigenetic regulation of gene expression are characteristic features of malignant neoplasms. Combinations of these abnormalities form molecular features of individual tumors. In the large-scale Dependency Map (DepMap) project, the broad panels of human tumor cell lines are being tested for sensitivity to single gene inactivation. Using DepMap data, we have previously identified a set of genes termed supertargets, the deletion of which significantly reduced the survival of cells of a particular tissue origin while minimally impairing the unrelated cell lines. In the present study, we determined the factors of viability (inhibition of proliferation or death) of cell lines in which the supertarget genes have been deleted. We found that, in 79 % of cases, the reduced survival may be caused by epigenetic changes of gene expression. In the remaining 21 % of cases, it is associated with altered gene structure. Three groups containing different types of gene expression alterations can be distinguished. In the first group, the reduced cell survival correlated with a higher expression of the supertarget gene (e. g., SOX10 and HNF1B). In the second group, a gene different from the deleted supertarget was overexpressed (gene pairs: FOXA1 and SPDEF, TP63 and SERPINB13, etc.). The third group was characterized by correlations between low expression of a certain gene and tumor cell sensitivity (e. g., FAM126A and FAM126B, SMARCA2 and SMARCA4). The genetic changes included GOF mutations (KRAS, BRAF genes, etc.), LOF mutations (STAG1, SMARCA2 genes, etc.), gene fusions (BCR-ABL1, PAX3-FOXO1, etc.), and amplification (CPM, BEST3, etc.). Therefore, many different molecular mechanisms act as predictors of tumor cell response to inhibition of supertarget genes. - Source: PubMed
Chetverina D AKozelchuk N YLomaev D VShtil A AErokhin М M - Precise control of DYRK1A dosage is essential for embryonic development, including craniofacial morphogenesis. While LZTS2 is among the most consistently identified DYRK1A-interacting proteins, its roles in embryonic development remain incompletely understood, and its potential contribution to craniofacial development has not been examined. was used to test the role of LZTS2 in craniofacial development and its functional relationship with DYRK1A. - Source: PubMed
Publication date: 2026/04/02
Cheng NicoleLima SantiagoLitovchick LarisaDickinson Amanda Jg